177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor

被引：2

作者：

Ventura, David ^{[1
]}

Roll, Wolfgang ^{[1
]}

Kasper, Hans-Udo ^{[2
]}

Rahbar, Kambiz ^{[1
]}

Stegger, Lars ^{[1
]}

机构：

[1] Univ Hosp Muenster, Dept Nucl Med, Albert Schweitzer Campus 1,Gebaude A1, D-48149 Munster, Germany

[2] Clemenshosp Muenster, Inst Pathol, Munster, Germany

来源：

CLINICAL NUCLEAR MEDICINE | 2023年 / 48卷 / 12期

关键词：

PRRT; GEP-NET; PET/CT; DOTATATE; SSTR; ANALOG;

D O I：

10.1097/RLU.0000000000004888

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A 73-year-old man with metastatic pancreatic neuroendocrine tumor was evaluated with Ga-68-DOTATATE PET/CT for peptide receptor radionuclide therapy. Both PET-positive and negative lesions were seen in the liver, along with extrahepatic metastases. Histopathology was obtained from one of the PET-negative liver lesions to exclude secondary malignancy. Histology confirmed a well-differentiated (G2) metastasis of pNET with high somatostatin receptor expression. We initiated peptide receptor radionuclide therapy with close monitoring of the PET-negative liver metastases. We present a rare case, where posttherapeutic scintigraphy revealed vigorous uptake of Lu-177-DOTATATE even in the Ga-68-DOTATATE PET-negative liver metastases. Follow-up PET/CT showed a partial response to therapy.

引用

页码：E585 / E587

页数：3

共 50 条

[1] Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
Zahed, Hanan
Beauregard, Jean-Mathieu
Abikhzer, Gad
Rush, Christopher
Probst, Stephan
CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E12 - E15
[2] Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
Ortega, Claudia
Wong, Rebecca K. S.
Schaefferkoetter, Josh
Veit-Haibach, Patrick
Myrehaug, Sten
Juergens, Rosalyn
Laidley, David
Anconina, Reut
Liu, Amy
Metser, Ur
JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1406 - 1414
[3] Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
Mittra, Erik S.
AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 278 - 285
[4] Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT
Hoberueck, Sebastian
Michler, Enrico
Zoephel, Klaus
Platzek, Ivan
Kotzerke, Joerg
Brogsitter, Claudia
CLINICAL NUCLEAR MEDICINE, 2019, 44 (01) : 50 - 52
[5] Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors
Wong, Ka Kit
Frey, Kirk A.
Niedbala, Jeremy
Kaza, Ravi K.
Worden, Francis P.
Fitzpatrick, Kellen J.
Dewaraja, Yuni K.
NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (08) : 892 - 900
[6] Visual and whole-body quantitative analyses of 68Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE
Hotta, Masatoshi
Sonni, Ida
Thin, Pan
Nguyen, Kathleen
Gardner, Linda
Ciuca, Liliana
Hayrapetian, Artineh
Lewis, Meredith
Lubin, David
Allen-Auerbach, Martin
ANNALS OF NUCLEAR MEDICINE, 2024, 38 (04) : 296 - 304
[7] 68Ga-DOTATATE PET/CT Findings of Cervical Esophageal Neuroendocrine Tumor
Filizoglu, Nuh
Ozguven, Salih
CLINICAL NUCLEAR MEDICINE, 2021, 46 (07) : E393 - E394
[8] Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT
Sanli, Yasemin
Garg, Ishan
Kandathil, Asha
Kendi, Tuba
Zanetti, Maria J. Baladron
Kuyumcu, Serkan
Subramaniam, Rathan M.
AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 267 - 277
[9] The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE
Kepenek, Ferat
Komek, Halil
Can, Canan
Kaplan, Ihsan
Altindag, Serdar
Gundogan, Cihan
NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (06) : 509 - 517
[10] Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT
Ulaner, Gary A.
Bodei, Lisa
CLINICAL NUCLEAR MEDICINE, 2019, 44 (04) : 330 - 331

← 1 2 3 4 5 →